{
  "trial_id": "NCT02464891",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age >18 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Diagnosis of aHUS with or without identified genetic abnormalities in the complement system or thrombomodulin",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Stable chronic extracorporeal or peritoneal dialysis therapy since at least 6 months",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Written informed consent",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Women of childbearing potential or women who are breastfeeding",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Shiga toxin-associated HUS or secondary forms of thrombotic microangiopathy",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "ADAMTS13 activity <10 % or circulating anti ADAMTS13 autoantibodies consistent with the diagnosis of thrombotic thrombocytopenic purpura",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Need for specific intervention with plasma therapy and/or complement inhibitors as deemed clinically appropriate",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "The patient has a history of atypical hemolytic uremic syndrome (aHUS) and has been previously vaccinated. He is currently being treated with plasma exchange and corticosteroids.",
  "_meta": {
    "topic_id": "68",
    "trial_id": "NCT02464891",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}